Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Abstract: Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17?-hydroxysteroid dehydrogenase (17?-HSD) such as 17?-HSD type 1, type 2 or type 3 enzyme.

Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Abstract: Use of bacterial strains of the species Amycolatopsis mediterranei for microbial transformation of 9?,10?-steroids of formula (I) to their corresponding 11?-hydroxyl analogues, as well as specific strains of that species, a process for transforming 9?,10?-steroids to their corresponding 11?-hydroxyl derivatives using bacterials strains of the species Amycolatopsis mediterranei, and subsequent isolation of the 11?-hydroxyl derivatives from the bacterial culture medium. The resulting 11?-hydroxylated products are useful intermediates for preparing novel steroidal compounds with 9?,10?-confirmation carrying different kinds of substituents in the 11?-position.

Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Abstract: The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17?-hydroxysteroid dehydrogenase type I (17?-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration.

Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Abstract: 3,15-substituted estrone compounds which act as inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration, as well as the general use of selective 17?-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment or inhibition of benign gynecological disorders, particularly endometriosis.

Abstract: Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17?-hydroxysteroid dehydrogenase enzymes.

Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Abstract: Pharmacologically active compounds of the general formula I wherein R1 is an alkyl group with 1-6 carbon atoms or a cycloalkylalkyl group with 4-7 carbon atoms, R2 is lower alkyl, and R3 is lower alkyl, or R2 and R3 together form an alkylene chain with 3-6 carbon atoms, and R4 represents a phenyl radical monosubstituted in the ortho or para position by nitro, cyano or lower alkanoyl or disubstituted in the ortho and para positions by nitro, and their physiologically compatible acid addition salts are described.

Abstract: Pharmacologically active compounds of the general formula I 1

Abstract: The invention relates to a device or equipment as well as to a method for the simultaneous, fractionating operation of a plurality of parallel chromatographic columns. It is particularly advantageous to apply this equipment and method in research, in the framework of organic synthesis for simultaneous, parallel separation, isolation and purification of a plurality of chemical compounds, e.g. of potential new active ingredients for medicaments, particularly also on the semi-preparative scale.

Abstract: Compounds with neutral endopeptidase (NEP) inhibitory activity corresponding to the formula I ##STR1## in which R.sup.1 is a lower alkoxy-lower-alkyl group whose lower alkoxy radical is substituted by a lower alkoxy group, or a phenyl-lower-alkyl or phenyloxy-lower-alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or a naphthyl-lower-alkyl group,A is CH.sub.2, O or S,R.sup.2 is hydrogen or halogen,R.sup.3 is hydrogen or halogen,R.sup.4 is hydrogen or a group forming a biolabile ester, andR.sup.5 is hydrogen or a group forming a biolabile ester, and the physiologically acceptable acid addition salts thereof.